Crossover hits overall survival, pouring doubts on the group’s deal hopes.

The study of Novartis’s Pluvicto in pre-chemo prostate cancer is a bust on overall survival, with questions raised about trial design.

Leaked data ahead of the ESMO late breaker show a progression-free survival benefit that looks practice-changing.

Beyond lung cancer this year’s ESMO promises several other late-breaking datasets that could change clinical practice.

The company’s radiopharmaceutical PNT2002 faces a major fourth-quarter catalyst, and US filing could follow.